Mast Therapeutics Inc (NYSE MKT LLC:MSTX)
| 0.437 Data as of Jan 30 |  +0.0065 / +1.51%Today’s Change | 0.40 Today|||52-Week Range 0.93 | -21.96% Year-to-Date |
| SECTOR Health Technology | INDUSTRY Biotechnology | MARKET CAP $69.5M |
Company Description
Mast Therapeutics, Inc. is a biopharmaceutical company that is engaged in developing novel therapies for serious or life-threatening diseases with significant unmet needs. Its lead product MST-188 has cytoprotective and hemorheologic properties and inhibits inflammatory processes and thrombosis. The company was founded by Warren C. Lau in December 1995 and is headquartered in San Diego, CA.
Contact Information
Mast Therapeutics, Inc. 12390 El Camino Real San Diego California 92130 |
Employees
Shareholders
| Other institutional | 8.73% |
| Mutual fund holders | 10.20% |
| Individual stakeholders | 0.27% |
Top Executives
| Brian M. Culley | Chief Executive Officer & Director |
| Patrick L. Keran | President, Chief Operating Officer & Secretary |
| Brandi L. Roberts | Chief Financial Officer, CAO & Senior VP |
| Edwin L. Parsley | Chief Medical Officer & Senior Vice President |
| Robert Martin Emanuele | Senior Vice President-Development |
.